Extinction is still forever, but scientists at the biotech company Colossal Biosciences are trying what they say is the next ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Learn how CASGEVY, the first NHS-approved CRISPR gene therapy, treats sickle cell disease through a revolutionary genetic ...

The decision reinstates unscientific regulation of new plant varieties, contradicting not only decades of experimentation, ...

Johns Hopkins scientists say the innovation could bring 'new fruits, foods, and flavors' to an expanded global agricultural ...

The USA animal model market has reached a significant milestone, attaining an estimated valuation of USD 976.1 million in ...

As layoffs continue to strike biopharma outfits big and small, life sciences technology and service provider Cytiva is ...

Colossal Biosciences has engineered mice with mammoth-like traits for living in cold climates. These mice have wavy, golden ...

Three studies led by faculty of Penn’s Perelman School of Medicine were selected for the Clinical Research Forum’s “Top Ten ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...

After an illustrious career, including 12 years as director of the NIH and leading the HGP consortium, Francis Collins announces his sudden resignation.

When you hear about sickle cell disease being cured because of CRISPR gene editing, that was built on many years of research supported by NIH,” Collins wrote. Collins, 74, was the NIH’s director for ...